Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Kamlesh Khunti F MedSciHungta ChenJavier Cid-RuzafaPeter FeniciMarília Brito GomesNiklas HammarLinong JiMikhail KosiborodStuart PocockMarina V ShestakovaIichiro ShimomuraFengming TangHirotaka WatadaAntonio Nicoluccinull nullPublished in: Diabetes, obesity & metabolism (2019)
The poor levels of glycaemic control at initiation of second-line therapy suggest that intensification of glucose-lowering treatment is delayed in many patients with T2D. In some countries, HbA1c levels are not routinely measured. These findings highlight an urgent need for interventions to improve monitoring and management of glycaemic control worldwide, particularly in lower-middle- and upper-middle-income countries.